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DMNG-3 (3β-Methyl-[2-(4-nitrophenoxy)ethyl]-amino]con-5-enine), is a new and the potentially most potent acetylcholinesterase 
inhibitor recently obtained from conessine by N-demethylation and nucleophilic substitution reaction. In the present study, a step-down 
passive avoidance test was used to investigate whether DMNG-3 could modulate impairment of learning and memory induced by 
scopolamine, and a high performance liquid chromatography (HPLC) method for the determination of DMNG-3 in biological samples was 
applied to study its pharmacokinetics and tissues distribution. Separation was achieved on C18 column using a mobile phase consisting 
methanol-water (70:30, v/v) at a flow rate of 1.0 ml/min. The intra- and inter-day precisions were good and the RSD was all lower than 
1.30%. The mean absolute recovery of DMNG-3 in plasma ranged from 88.55 to 96.45%. Our results showed oral administration of 
DMNG-3 (10, 25, 50 mg/kg/day) can significantly improve the latency and number of errors and had a positive effect of improvement 
of learning and memory in mice in passive avoidance tests. The elimination half-life (T1/2) was 14.07±1.29, 15.87±1.03 h, and the total 
clearance (CL) values were 0.70±0.11, 0.78±0.13 L/h/kg, respectively. The pharmacokinetic studies showed that DMNG-3 has a slowly 
clearance and large distribution volume in experimental animals, and its disposition is linear over the range of doses tested. The liver, 
small intestine, stomach, and large intestine were the major distribution tissues of DMNG-3 in mice. It was found that DMNG-3 could 
be detected in brain, suggesting that DMNG-3 can cross the blood-brain barrier. The present study shows that DMNG-3 can be possible 
developed as a new drug for the treatment of Alzheimer’s disease in the future. 
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INTRODUCTION
Alzheimer’s disease (AD) is a common form of dementia, 
characterized by the degeneration of basal forebrain 
cholinergic neurons innervating the cortex amygdale and 
hippocampus, with difficulty in maintaining and sustaining 
attention, and with profound cognitive impairment, such 
as loss of memory and learning ability (Michael et al. 2003, 
Lanz et al. 2004, Fodale et al. 2006). Four different forms 
of AD are reported: with delirium, with delusions, with 
depressed mood and uncomplicated, each indicating the 
predominant feature of clinical presentation. The course 
of the disease is fluctuant, and cognitive impairment, 
personality change, psychotic symptoms, incontinence, 
gait and motor disturbance, seizures and myoclonus can 
occur. These cognitive deficits cause significant impairment 
in social and occupational function. 
AD is a progressive neurodegenerative disorder which 
is characterized by memory loss and other cognitive 
impairments. There is not a clear theory on disease due to 
its complex etiology. AD includes several diverse hallmarks 
such as β-amyloid deposits, τ-protein aggregation, oxidative 
stress, or low levels of acetylcholine (ACh) (Morain et al. 
2000). The cholinergic hypothesis of AD suggests that low 
levels of ACh in specific regions of the brain result in learning 
and memory dysfunction. This hypothesis indicates that 
increase of ACh levels by inhibition of acetylcholinesterase 
(AChE) is beneficial for the treatment of AD. Today, AChE 
inhibitors are first-line medications for the treatment of 
AD, and are associated with mild improvements in cognitive 
function, behavior, and activities of daily living; However, 
the most adverse effects of AChE inhibitors, such as nausea, 
vomiting, diarrhea, dizziness, confusion, and cardiac 
arrhythmia, are still inevitable (Wilkinson et al. 2004, Winslow 
et al. 2011). Recently, 11 new AChE inhibitors were obtained 
from conessine by N-demethylation and nucleophilic 
substitution reaction. The most potent potential inhibitor 
was DMNG-3 (3β-Methyl-[2-(4-nitrophenoxy)ethyl]-amino]
con-5-enine, Fig. 1) with a 4-nitrophenoxyethyl at 3-N 
position of isoconessimine, which showed an IC50 value 
of 0.11 μmol/L, being close to those of huperzine A (IC50, 
0.07 μmol/L) (Jin et al. 2013). © 
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Although DMNG-3 showed a higher inhibition of AChE 
activity, little is known regarding their biological activity in 
vivo and pharmacokinetic studies. Poor pharmacokinetics 
is one of the reasons for the withdrawal of drug candidates 
from clinical trials (Kuuranne et al. 2008). Thereby, the 
objective of this study was to develop a step-down passive 
avoidance test to investigate whether DMNG-3 could 
modulate impairment of learning and memory induced by 
scopolamine. In addition, a sensitive and precise analytical 
method for determining DMNG-3 in biological samples was 
applied and further to understand its pharmacokinetic 
characteristics and tissues distribution in rats after oral 
administration. Our results suggested that DMNG-3 can 
be possible developed as a new drug for the treatment of 
Alzheimer’s disease in the future.
METHOD
Chemical reagents 
The baicalein was purchased from the company of 
Biotechnology company of ShangHai YuanYe, with over 
98% purity. DMNG-3 was offered by School of Life Science 
and engineering of Lanzhou university of technology, with 
over 98% purity. The chromatographic methanol purchased 
from the company of DaMao chemical reagent factory in 
TianJin. Deionized water was purchased from the company 
of WaHaHa in HangZhou. Huperzine A was purchased from 
the Wanbang pharmaceutical company in ZheJiang. The 
Scopolamine hydrobromide was purchased from the first 
pharmaceutical company in ChengDu. Other reagents were 
all of analytical grade. 
Step-down passive avoidance test 
ICR mice, weighing 20±2 g, were obtained from the Lanzhou 
university animal center. According to the requirement of the 
National Act on the Use of Experimental Animal (People’s 
Republic of China); the protocols of animal experiments 
were approved by the Animals Ethics Committee of Lanzhou 
University of Technology. For the pharmacodynamics 
study, 60 ICR mice were randomly assigned to six groups: 
1 – normal group; 2 – scopolamine-treated for control group; 
3 – scopolamine with 2 mg/kg Huperzine A for positive control 
group; 4–6 – scopolamine with 10, 25, 50 mg/kg DMNG-3 
for Drug treatment groups. The positive control group 
(2 mg/kg/day Huperzine A) and three DMNG-3 treatment 
groups (10, 25 and 50 mg/kg/day) were orally administered 
indicated doses for 15 days in a row once daily prior to testing 
in the apparatus. The normal groups and control groups 
were orally administrated 0.2 ml saline per 20 g for 15 days. 
Scopolamine (3 mg/kg, ip) was given to all scopolamine-
-treated groups 60 minutes before testing.
The inhibitory avoidance apparatus was a 50×25×25-cm 
xyloid box whose floor consisted of brass wires (1 mm in 
diameter) spaced 1 cm apart. A 6 cm wide, 2.5 cm high 
platform was placed on the floor of the box against the 
left wall. Animals were placed on the platform and their 
latency to step down on the grid with all four paws was 
measured. At the beginning of training trial, mice were 
placed in the box to adapt for 3 min. In the training session, 
mice were exposed to a 5 min learning course, during 
which they received an electric foot shock (36 V, AC) if the 
animals stepped down from the platform. After 24 h, in the 
test session, 24 h after the training test was performed, 
and mice were placed on the platform. The latency to step 
down onto the grid for the first time and the number of 
errors when subjected to shocks with 5 min (the shocks 
were maintained for 5 min) were measured as learning 
performances (Roesler et al. 2000, Wu et al. 2012). 
Chromatographic equipments and conditions 
The HPLC system consists of a PU-2086 pump, 
a 2487 UV/VIS detector set at 300 nm, and a Mx-2080-31. 
The analyzes were separated on a Kromasil ODS C18 
reversed-phase column (4.6×250 mm, 5 µm) at the room 
temperature with the mobile phase of methanol-water 
(70:30 v/v) at a flow rate of 1.0 ml/min. 
Plasma sample preparation
The IS solution (50 μl, 5 μg/ml in methanol) was added 
to 100 μl of plasma samples or tissue homogenate samples, 
then the mixture was precipitated with 500 μl methanol. 
After vortexing for 5 min, the denatured protein precipitate 
was separated by centrifugation at 12000 rpm for 10 min at 
room temperature (Adessi et al. 2003, Li et al. 2012). The 
supernatant was evaporated to dryness in a water-bath 
at 37°C and then dissolved in 100 μl mobile phase. A 20-μl 
volume of this sample solution was injected onto HPLC 
for analysis. Simple one-step protein precipitation with 
Fig. 1. Chemical structures of DMNG-3 (3β-Methyl-[2-(4-nitrophenoxy)
ethyl]-amino]con-5-enine).
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methanol was used to minimize baseline distortion and 
optimize extraction recovery (Hasim et al. 2011). 
Preparation of calibration standards, quality 
control samples and low limit of quantitation
The configuration of the DMNG-3 standard solution: 
DMNG-3 (10 mg) and internal standard (IS) (10 mg) were 
prepared by accurately weighing the required amounts 
into separate volumetric flasks and dissolving in methanol. 
The methanol stock solution of DMNG-3 was serially diluted 
to get the standard working solutions with the desired 
concentrations: 0.08, 0.1, 0.2, 0.5, 1.0, 10.0 μg/ml for plasma 
and 0.08, 0.1, 0.2, 0.5, 1.0, 10.0 μg/ml for tissue homogenates 
and IS was diluted to 10 μg/ml with methanol. All solutions 
were stored at 4°C (Li et al. 2012).
Quality control (QC) standards were prepared by 
spiking blank plasma with appropriate volumes of DMNG-3 
standard solutions to make low, medium and high drug 
concentrations of 0.08, 0.20, 1.00 μg/ml, respectively. 
Preparation and extraction of the plasma samples and the 
spiked samples were carried out as the above-mentioned 
extraction method. A standard curve was constructed by 
plotting the observed peak area ratios of DMNG-3 and IS 
against the respective standard concentration using the 
least-squares method. 
The low limit of quantification (LLOQ) in plasma was 
defined as ten times the signal-to-noise ratio (S/N) and the 
lowest concentration on the calibration curve for which an 
acceptable accuracy (RE) within ±20% and a precision (RSD) 
below 20% can be obtained. 
Accuracy and precision
For the determination of intra-day and inter-day 
accuracy and precision of the proposed method, the QC 
samples at low, medium and high levels (0.08, 0.20, and 
1.00 μg/ml) were repeatedly injected into the HPLC column. 
In order to determine intra-day accuracy and precision, 
the assays were carried out on the same samples at five 
duplicates on the same day. This process was repeated on 
three consecutive days in order to determine the inter-day 
accuracy and precision. The precision was expressed as 
the relative standard deviation (RSD), and intra- and inter-
day assay accuracies were described as percentages of 
theoretical concentration (Lin et al. 2010, Kwon et al. 2004).
Extraction recovery
The recovery of the DMNG-3 was calculated by the 
comparison between peak areas of the calibration samples 
analyzed by the normal procedure and those obtained after 
adding the same amounts of reference substances to blank 
plasma after extraction. Experiments were performed at 
the three QC concentration levels (0.08, 0.20, 1.00 μg/ml) in 
triplicate (Lin et al. 2010). 
Stability study of plasma sample
The stabilities of the analyte in plasma were assessed 
by analyzing triplicate QC samples. These QC samples 
were stored at −20°C for 2 weeks, then all samples were 
thawed and analyzed along with the freshly prepared set 
of QC samples for storage stability study (Lin et al. 2010, 
Zhuang et al. 2011, Wang et al. 2011). Moreover, the QC 
samples were determined after three freeze-thaw cycles 
and the concentration were compared to their nominal 
concentration for freeze-thaw stability testing study. 
Pharmacokinetic study 
The healthy sprague-dawley (SD)） rats (220±20 g) were 
provided from the Experimental Animal Center of Lanzhou 
University (GanSu, China). According to the requirement 
of the National Act on the Use of Experimental Animal 
(People’s Republic of China); the protocols of animal 
experiments were approved by the Animals Ethics 
Committee of Lanzhou University of Technology. For the 
pharmacokinetic study, 12 SD rats were randomly assigned 
to 2 groups and each group contained 6 rats, respectively. 
According to the results of step-down passive avoidance 
test, the SD rats were orally administered DMNG-3 
DMSO solution which was suspended by 0.5% CMC-Na 
(DMSO<10%) at the dose of 20 mg/kg, 40 mg/kg. 250 μl 
blood samples were collected in heparin containing tubes 
from the retro-orbital plexus of rats at times 0, 0.5, 1, 3, 5, 
8, 12, 16 24, 36, 48 and 72 h after oral administration, and 
immediately centrifuged at 5000 RPM for 10 min (Hasim 
et al. 2011, Zhuang et al. 2011, Lin et al. 2009). The plasma 
samples were frozen at −20°C until analysis.
Tissue distribution study
30 ICR mice were randomly assigned to 3 groups, 
respectively. Each group contained 10 mice, DMSO solution 
of DMNG-3 was suspended by 0.5% CMC-Na (DMSO<10%) 
was administered orally at a dose of 25 mg/kg to each 
group. The different tissue including the heart, liver, 
lung, spleen, kidney, brain, stomach, small intestine, large 
intestine and fat samples were collected at 6, 9, and 12 h, 
respectively (Hasim et al. 2011, Zhang et al. 2003). These 
time points were selected on the basis of pharmacological 
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and pharmacokinetic studies in rats. Tissue samples were 
individually homogenized with normal saline at the rate of 
1:1 (weight/volume) using an homogenizer. The obtained 
tissue homogenates were centrifuged at approximately 
12,000 rpm for 10 min and supernatants were stored at 
−20°C until analysis (Wang et al. 2012, Guo et al. 2013, Hao 
et al. 2005).
Data analysis
Pharmacodynamic data were analyzed by one-way 
analysis of variance followed by Duncan’s multiple range 
test when the T-test was significant, and which using the 
SPSS 17.0 software. Statistically significant differences 
between control and experimental groups (P<0.05) are 
indicated.
Pharmacokinetic parameters of DMNG-3 were calculated 
by non-compartmental and compartmental methods using 
the DAS 3.0 software (Medical College of Wannan, People’s 
Republic of China). The maximum plasma concentrations 
(Cmax) and the time to reach the maximum concentrations 
(Tmax) were obtained directly from the observed data. 
The elimination rate constant (kel) was calculated on the 
slope of terminal portion of the log-transformed plasma 
concentration versus time curve by linear regression. The 
elimination half-life (T1/2) was calculated using 0.693/kel. 
The area under curve from 0 hour to t (AUC0）t) in rats was 
calculated via the trapezoidal rule. The area under the 
plasma concentration-time curve to time infinity (AUC0–∞) 
was calculated as AUC0–∞=AUC0–t+Ct/Kel, with ‘Ct’ defined as 
the last measured plasma concentration at time t (Wang et 
al. 2011). 
RESULTS AND DISCUSSION
Effects of DMNG-3 on acquisition of memory in 
step-down passive avoidance test
AD is one of the most frequent causes of dementia, 
representing 50–60% of all dementia cases and affecting 
10–20% of people older than 65 years. Although many 
intellectual functions are impaired (attention, orientation, 
language, judgment), the most prominent symptom of AD 
is represented by a progressive memory loss (Winslow et 
al. 2011). In general, memory processes are divided into 
three stages: learning acquisition, memory retention, 
and reappearance (Lu 2001). The step-down type passive 
avoidance is used to measure the three stages of memory 
process depending on drug-treated period. Chemical agents 
such as scopolamine, sodium nitrite, and 45% ethanol can 
cause memory impairment in mice (Luo et al. 2003). In this 
present paper, as can be seen from the Figure 2, in the control 
group, the latencies were significantly shortened and the 
number of errors markedly increased compared with the 
normal group in the step-down test (p<0.01). After mice were 
orally administered DMNG-3 (10, 25 and 50 mg/kg/day) for 
15 days in a row, the influence of DMNG-3 on AD model mice 
is obviously higher than control group and the latencies 
were significantly increased compared with the control 
rats (p<0.05, p<0.01). In addition, the errors number of mice 
administered DMNG-3 (10, 25 and 50 mg/kg/day) for 15 days 
in a row were significantly decreased compared with the 
control group (p<0.05, p<0.01). 
Huperzine A, derived from the Chinese herb Huperzia 
serrata as a potent, reversible, selective inhibitor of AChE, 
which has a mechanism of action similar to donepezil, 
rivastigmine and galantamine. A large number of preclinical 
studies and clinical trials had shown the effect of Huperzine 
A in treating AD (Yang et al. 2013). In our study, in the high 
dose group, the latencies were no significantly shortened 
and the number of errors markedly increased compared 
with Huperzine A-the positive drug group in the step-down 
test (p>0.05). 
AD is a neurodegenerative disorder characterized by 
a progressive loss of memory and cognition. It has long 
been recognized that the cholinergic system is critically 
involved in the control of cognition, and AD can be 
reversed by preventing the breakdown of Ach in the 
synaptic cleft with AChE inhibitors (Yan and Feng 2004, 
Wu et al. 2012). Our results demonstrated that DMNG-3 
can significantly improve the learning performances in 
scopolamine-induced learning and memory impairments 
in mice with increasing latency and a decreasing number 
of errors in the step-down test in a dose-dependent 
manner, which indicated that DMNG-3 might be useful for 
the treatment of AD. 
Fig. 2. The effect of DMNG-3 on scopolamine-induced learning and 
memory impairment in the Step-down test. *P<0.05, **P<0.01 compared 
with the control group, and ##P<0.01 compared with the normal group.
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Method validation
Specificity
A wavelength of 300 nm was chosen according to 
maximum absorption spectrum of DMNG-3 to achieve 
a high selectivity. Representative chromatograms of 
blank plasma sample, plasma spiked with 100 µg/ml of 
DMNG-3, plasma sample at 6 h after administration of 
DMNG-3 at a dose of 20 mg/kg are presented in (Fig. 3). The 
mobile-phase composition played a vital role in obtaining 
appropriate retention time and higher mass spectrum 
sensitivity. The mobile phase consisting of A methanol 
and B H2O (70:30, v/v)was approved to be optimal for this 
study. Several possible internal standards were tested 
including Acetic acid-alpha naphthyl esters, baicalein, 
baicalin, alantolactone. Acetic acid-alpha naphthyl 
esters and alantolactone were firstly considered as IS, 
but DMNG-3 had peaks that could not be separated with 
them. The extraction efficiency and chromatographic 
behavior of baicalein (5-, 6-, 7-trihydroxyflavone) were 
similar to those of DMNG-3, so it was tested in the same 
conditions as DMNG-3, and good peak shape in a proper 
time was achieved. Retention times of DMNG-3 and IS were 
approximately 15 and 18 min, respectively. There was no 
interfering peak from endogenous substances in the blank 
plasma and tissue.
Linearity of Calibration Curves and Limit of Determination
The standard curve was prepared for DMNG-3 in the 
range of 0.08–10.00 µg/ml, which covered the levels 
following the administration of a single dose of 20 mg/kg 
DMNG-3. The standard curve was described by equations 
are listed in Table 1, where y is the DMNG-3-to-IS 
peak-area ratio, x the concentration, and the correlation 
coefficient and the linear ranges for DMNG-3 correlation 
coefficients and linear ranges of DMNG-3 in each tissue 
are also listed in Table 1. The LOQ in plasma was defined 
as the lowest concentration that can be determined 
with relative error and relative standard deviation 
(RSD) <10%, LODs for Plasma and different tissues are 
also shown in Table 1.
Recovery
The recoveries of DMNG-3 from the rat plasma 
were 88.55±0.99%, 89.49±1.36%, and 96.45±0.63% for low 
(0.08 μg/ml), medium (0.20 μg/ml), and high (1.00 μg/ml) 
concentrations, respectively. The results are summarized 
in Table 2, and the mean recovery in most tissues at three 
different concentrations were all above 83.19%.
Precision and Accuracy
The intra-and inter-day accuracies were estimated 
and the studied concentrations (0.08 µg/ml, 0.20 µg/ml, 
Fig. 3. Representative HPLC Chromatograms of (A) blank rat plasma 
sample; (B) blank rat plasma spiked with DMNG-3 and the IS; (C) rat plasma 
sample obtained after administration DMNG-3 (1: DMNG-3, 2: IS).
Table 1. Regression equation, linear ranges and detection limits of the method
sample standard curve R2 linear range (μg/ml) LOD (μg/ml)
plasma y=2.5336x−0.0318 0.9999 0.08–10.00 0.08
heart  y=2.347x−0.0053 0.9969 0.08–10.00 0.08
liver  y=2.603x−0.0411 0.9995 0.08–10.00 0.08
spleen y=2.4456x−0.0104 0.9993 0.08–10.00 0.08
lung y=2.5963x−0.0368 0.9996 0.08–10.00 0.08
kidney   y=2.3254x+0.012 0.9976 0.08–10.00 0.08
large intestine y=2.6256x−0.0618 0.9998 0.08–10.00 0.08
small intestine y=2.5951x−0.0456 0.9995 0.08–10.00 0.08
stomach y=2.3489x+0.0108 0.9987 0.08–10.00 0.08
fat y=2.3415x+0.0189 0.9987 0.08–10.00 0.08
brain   y=2.346x+0.0268 0.9973 0.08–10.00 0.08
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1.00 µg/ml) were lower than 10%, and the accuracy was 
within ±1.30%, These values were within the acceptable 
range (±15%) indicating that the present method had a 
good accuracy and precision. The result of accuracy and 
precision were presented in Table 3.
Stability
The stability of DMNG-3 in samples was investigated 
under a variety of storage and process conditions. For 
storage stability, samples were prepared and stored at −20°C 
for 2 weeks. On the 15th day, all samples were thawed and 
analyzed along with the freshly prepared set of the quality 
control (QC) samples. Analysis of these samples were equal 
to the freshly prepared samples (RSD<15%). The results 
showed that all the samples were stable during these tests, 
and there were no stability-related problems during the 
routine analysis of samples.
Application to pharmacokinetics study
In order to ensure enough plasma containing DMNG-3 
to analysis in the current pharmacokinetic study, 
pharmacokinetic data was obtained from rats but mice; 
Furthermore, the conversion of drug doses between species 
were used, and dose is adjusted and rounded from 25.50 mg/kg 
to 20.40 mg/kg, respectively. The method described above 
was successfully applied to a pharmacokinetics study in 
rat after oral administration of 20.40 mg/kg DMNG-3. The 
mean plasma concentration-time profiles of DMNG-3 are 
shown in (Fig. 4). Based on these results, the PK parameters 
were calculated and summarized in Table 4 (Li et al. 2012, 
Hasim et al. 2011, Lin et al. 2009). 
After oral administration, DMNG-3 was absorbed slowly 
from rat gastrointestinal tract; the drug was detected in 
plasma from the first blood sampling time (30 min) and 
slowly reached Tmax values of 12.59±0.17, 16.13±0.23 h for 20 
and 40 mg/kg, respectively. DMNG-3 showed slowly systemic 
clearance (CL 0.70±0.11, 0.78±0.13 L/h/kg) and big volume of 
distribution (Vd 16.05±0.14, 15.85±0.10 L/kg). The volume of 
distribution was almost 20 times total body water at 0.668 L/kg 
in rats (Davies et al. 1993), suggesting that DMNG-3 may be 
more distributed into extravascular systems. Moreover, the 
elimination half-life (T1/2) was 14.07±1.29, 15.87±1.03 h. The 
corresponding value for AUC0–t and AUC0–∞ was 54.61±2.03, 
30.86±1.31, 57.09±1.97, and 32.01±1.72 μg/L.h, indicating that 
DMNG-3 was orally available. 
Application to tissues distribution study
Because the maximum concentration was at 12 h 
at the dose of 25 mg/kg, we chose 6, 9, and 12 h after 
Fig. 4. Mean plasma DMNG-3 concentration versus time profiles after oral 
administration with a single dose of 40 mg/kg, 20 mg/kg in SD rats (n=6).
Table 2. Recovery of DMNG-3 in plasma of rats (n=5)
spiked concentration 
(μg/ml)
recovery  
(Mean±SD, %) RSD (%)
0.08 88.55±0.99 1.12
0.20 89.49±1.36 1.52
1.00 96.45±0.63 0.67
Table 3. Precision and accuracy data for DMNG-3 in plasma of rats 
(n=3 days, 5 times per day)
concentration
μg/ml
intra-day inter-day
RSD (%) accuracy (%) RSD (%) accuracy (%)
0.08 0.72 92.63 0.75 95.14
0.20 1.03 93.47 1.30 92.29
1.00 1.03 97.16 0.94 91.35
Table 4. Main pharmacokinetic parameters of DMNG-3 after oral 
administration with two kinds dose of 40 mg/kg and 20 mg/kg to SD rats 
(X±SD, n=6) 
parameter unit
40 mg/kg 20 mg/kg
mean SD mean SD
AUC (0–t) μg/L.h   54.61 2.03  30.86 1.31
AUC (0–∞) μg/L.h  57.09 1.97   32.01 1.72
MRT (0–t) h   22.31 1.45  23.35 1.36
MRT (0–∞) h  25.46 1.69  25.82 2.06
Kel 1/h  0.04 0.01  0.05 0.01
T1/2 h  15.87 1.03  14.07 1.29
Tmax h  16.13 0.23  12.59 0.17
V L/kg  16.05 1.46  15.85 1.02
CL L/h/kg  0.70 0.11  0.78 0.13
Cmax μg/ml  2.06 0.21  0.97 0.11
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oral administration as the detected time points. In this 
experiment (n=10), we found that DMNG-3 could be detected 
in brain, suggesting that DMNG-3 can cross the blood-brain 
barrier and coincided with the influences of DMNG-3 
on step-down activities in AD model mice. At 3 h after 
administration, DMNG-3 could be detected in most of the 
inspected tissues as is shown in (Fig. 5). This suggested that 
DMNG-3 is mainly absorbed in large intestine and stomach 
and digested slowly. The content of DMNG-3 in liver and 
small intestine showed similar dynamic change: maximum 
concentration was at 12 h, which might mainly be attributed 
to the oral administration (Yan et al. 2005), but it showed 
that DMNG-3 has retention in most tissues, which made it 
necessary to further investigate whether it accumulations 
were toxic (Li et al. 2012, Zhang et al. 2003, Hao et al. 2005). 
CONCLUSIONS
For the first time, a simple and reliable HPLC method 
to determine DMNG-3 levels in rat plasma and different 
tissues was established and validated. The method has been 
also successfully applied to the pharmacokinetics studies 
and tissues distribution. In conclusion, the results of our 
study provide the first evidence that oral administration 
of DMNG-3 can ameliorate impaired learning and memory 
processes. Therefore, DMNG-3 may be a potent potential 
AChE inhibitor that can be used for the treatment of AD in 
the future. However, considerable research is still necessary 
to fully understand the potential utility of DMNG-3 in the 
treatment of cognitive dysfunction of AD. 
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